Search
for
Sort by
Research 31–60 of 775
- 69 Risk-benefit appraisal of systemic JAK inhibitors for alopecia areata: a comprehensive meta-analysis assessing safety and adverse effects
- Selective JAK 1 inhibition with upadacitinib as a potential treatment for coexistent severe atopic dermatitis and alopecia areata
- Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition
- Tofacitinib for the treatment of severe alopecia areata and variants: A study of 90 patients
- Oral ruxolitinib induces hair regrowth in patients with moderate-to-severe alopecia areata
- Killing Two Birds with One Stone: Oral Tofacitinib Reverses Alopecia Universalis in a Patient with Plaque Psoriasis
- An Open-Label Pilot Study to Evaluate the Efficacy of Tofacitinib in Moderate to Severe Patch-Type Alopecia Areata, Totalis, and Universalis
- Targeting the Janus Kinase Family in Autoimmune Skin Diseases
- Alopecia Areata: a Comprehensive Review of Pathogenesis and Management
- Tyrosine Kinases in Autoimmune and Inflammatory Skin Diseases
- The Changing Landscape of Alopecia Areata: The Therapeutic Paradigm
- The Role of Interferon-γ in Autoimmune Polyendocrine Syndrome Type 1
- Role of janus kinase inhibitors in the treatment of alopecia areata
- Novel TMEM173 Mutation and the Role of Disease Modifying Alleles
- Selective inhibition of JAK3 signaling is sufficient to reverse alopecia areata
- Baricitinib: From Rheumatoid Arthritis to COVID‐19
- Tofacitinib Citrate for the Treatment of Nail Dystrophy Associated With Alopecia Universalis
- Ruxolitinib for the treatment of severe alopecia areata
- The Safety and Efficacy of Tofacitinib in 24 Cases of Pediatric Rheumatic Diseases: Single Centre Experience
- STAT5 Activation in the Dermal Papilla Is Important for Hair Follicle Growth Phase Induction
- A novel therapeutic paradigm for patients with extensive alopecia areata
- New drugs under investigation for the treatment of alopecias
- Integrated safety analysis of baricitinib in adults with severe alopecia areata from two randomized clinical trials
- Treatment of severe alopecia areata with baricitinib
- Two cases of alopecia areata treated with ruxolitinib: a discussion of ideal dosing and laboratory monitoring
- Developing a JAK Inhibitor for Targeted Local Delivery: Ruxolitinib Cream
- Successful Treatment of Refractory Alopecia Areata Universalis and Psoriatic Arthritis, But Not of Plaque Psoriasis with Tofacitinib in a Young Woman
- Complete Regrowth of Beard Hair with Ruxolitinib in an Alopecia Universalis Patient
- Successful treatment of alopecia universalis with abrocitinib: a case report
- Treatment of moderate-to-severe alopecia areata in pre-adolescent children with baricitinib